

Clinical Trial Protocol

Iranian Registry of Clinical Trials

20 Jul 2026

Celecoxib in the treatment of depression in patients with Brucellosis: a double blind randomized trial

Protocol summary

Summary

The purpose of the present investigation is to assess the efficacy of celecoxib in the treatment of mild to moderate among patients with brucellosis in a eight-week double-blind, placebo controlled trial. 50 adult outpatients who meet the DSM-V criteria for major depression(mild to moderate) will participate in the trial. Patients who have a baseline Hamilton Rating Scale for Depression score below 20 will be randomly allocated into two groups. 25 persons will receive Cap. rifampin (600 to 900 mg/day)+ Doxycycline100 mg bid+ cap. celecoxib 200 mg bid for 8 weeks. 25 patients will receive Cap. rifampin (600 to 900 mg/day)+ Doxycycline100 mg bid+ placebo for 8 weeks. Patients will be assessed by a psychiatrist at baseline and after 2, 4 and 8 weeks after the medication started. Efficacy will be defined as the change from baseline to endpoint in score on Hamilton Rating Scale for Depression.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201405271556N59**

Registration date: **2014-05-29, 1393/03/08**

Registration timing: **prospective**

Last update:

Update count: **0**

Registration date

2014-05-29, 1393/03/08

Registrant information

Name

Shahin Akhondzadeh

Name of organization / entity

Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 21 5541 2222

Email address

s.akhond@sina.tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Tehran University of Medical Sciences

Expected recruitment start date

2014-06-22, 1393/04/01

Expected recruitment end date

2016-06-20, 1395/03/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Celecoxib in the treatment of depression in patients with Brucellosis: a double blind randomized trial

Public title

celecoxib in the treatment of depressed patients with brucellosis

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: 1-Confirmation of brucellusis, 2age between 18 to 50 years old, 3- score lower than 20 in Hamilton Rating Scale for depression 4-Mild to moderate major depressive disorder based on DSM-V Exclusion criteria: 1-duration of brucellosis more than 3 months, 2- presence of localized brucellosis(including endocarditis, osteomyelitis), 3-psychotic disorder, 4-receiving psychotropic medications, 5-receiving antidepressants during the last month 6-receiving antibiotics during the

last month, 7-patients who are under treatment with immunosuppressives, 8-history of cardiovascular disease, 9-pregnancy, 10-nursing women, 11-any significant medical condition(including malignancy, HIV infection, autoimmune disease,renal failure,hepatic failure), 12- other infectious diseases

Age

From **18 years** old to **50 years** old

Gender

Both

Phase

N/A

Groups that have been masked

No information

Sample size

Target sample size: **50**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Double blinded

Blinding description

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Tehran University of Medical Sciences

Street address

Keshvarz Blvd

City

Tehran

Postal code

Approval date

2014-05-01, 1393/02/11

Ethics committee reference number

24320

Health conditions studied

1

Description of health condition studied

Major depressive disorder

ICD-10 code

F32

ICD-10 code description

Major Depressive episode

Primary outcomes

1

Description

Severity of depression

Timepoint

Baseline and weeks 2-4-8 after beginig of treatment

Method of measurement

by Hamilton Depression Rating Scale 17-Item

Secondary outcomes

empty

Intervention groups

1

Description

Capsule Rifampine(900 mg/day in individuals with 75 kg weight or more and 600 mg/day in individuals with weight less than 75 kg)+ Cap. Doxycycline(100 mg bid)+ cap. celecoxib(200 mg bid) for 8 weeks

Category

Treatment - Drugs

2

Description

Capsule Rifampine(900 mg/day in individuals with 75 kg weight or more and 600 mg/day in individuals with weight less than 75 kg)+ Cap. Doxycycline(100 mg bid)+ cap. placebo for 8 weeks

Category

Placebo

Recruitment centers

1

Recruitment center

Name of recruitment center

Roozbeh Hospital

Full name of responsible person

Prof. Shahin Akhondzadeh

Street address

South Kregar street, Roozbeh Hospital

City

Tehran

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Tehran University of Medical Sciences

Full name of responsible person

Dr masoud yunesian

Street address

Keshvarz Blvd

City
 Tehran
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
 Yes
Title of funding source
 Tehran University of Medical Sciences
Proportion provided by this source
 100
Public or private sector
 empty
Domestic or foreign origin
 empty
Category of foreign source of funding
 empty
Country of origin
Type of organization providing the funding
 empty

Person responsible for general inquiries

Contact
Name of organization / entity
 Tehran University of Medical Sciences
Full name of responsible person
 Prof. Shahin Akhondzadeh
Position
 Prof. of Clinical Psychopharmacology
Other areas of specialty/work
Street address
 South Kargar street; Roozbeh Hospital
City
 Tehran
Postal code
Phone
 +98 21 5541 2222
Fax
Email
 s.akhond@sina.tums.ac.ir
Web page address

Person responsible for scientific inquiries

Contact
Name of organization / entity
 Tehran University of Medical Sciences
Full name of responsible person
 Prof. Shahin Akhondzadeh
Position

Prof. of Clinical Psychopharmacology
Other areas of specialty/work
Street address
 South Kargar Street; Roozbeh Hospital
City
 Tehran
Postal code
Phone
 +98 21 5541 2222
Fax
Email
 s.akhond@sina.tums.ac.ir
Web page address

Person responsible for updating data

Contact
Name of organization / entity
 Tehran University of Medical Sciences
Full name of responsible person
 Prof. Shahin Akhondzadeh
Position
 Prof. of Clinical Psychopharmacology
Other areas of specialty/work
Street address
 South Karegar street; Roozbeh Hospital
City
 Tehran
Postal code
Phone
 +98 21 5541 2222
Fax
Email
 s.akhond@sina.tums.ac.ir
Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)
 empty
Study Protocol
 empty
Statistical Analysis Plan
 empty
Informed Consent Form
 empty
Clinical Study Report
 empty
Analytic Code
 empty
Data Dictionary
 empty